BioSpace News Archive

Aadi Bioscience, Inc. today announced financial results for the first quarter of 2023 and provided an initial update on the tumor-agnostic PRECISION 1 trial, a registration-directed Phase 2 study of nab-sirolimus in patients with solid tumors with pathogenic inactivating alterations in TSC1 or TSC2 genes.

NeuroTrauma Sciences, LLC announced the expansion of its executive management team with key appointments: Marc de Somer, MD, ScD, MPH, MSc, MBA, has been appointed Chief Medical Officer and Martin Rabe, MSc, joins as Executive Vice President of Regulatory Affairs and Quality Assurance.

Harmony Biosciences Holdings, Inc. today announced that new safety and efficacy data from a Phase 2 proof-of-concept study evaluating pitolisant for the treatment of excessive daytime sleepiness in patients with Prader-Willi syndrome (PWS) will be highlighted as a poster presentation during a late-breaking abstract session at the 37th Annual Meeting of the Associated Professional Sleep Societies (APSS), known as “SLEEP 2023,” in Indianapolis from June 3-7.

Asembia’s 2023 Specialty Pharmacy Summit surpassed previous record attendance, cementing the conference’s role in bringing together industry leaders to discuss better ways to care for the most complex patients.

The Insight Partners published latest research report on “Neurotoxin Market Outlook Report, Size, Share, Trends & Growth to 2028 - COVID-19 Impact and Global Analysis By Product Type, Application, and End User”, the global market size is expected to reach USD 13,195.06 million by 2028 from USD 6,622.36 million in 2022; it is estimated to record a CAGR of 12.3% from 2023 to 2028.

Quest Diagnostics Incorporated, through the Quest Diagnostics Foundation, is proud to support the American Heart Association ‘s Hispanic Serving Institutions Scholars Program for the second year in a row.

CTI BioPharma announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB, a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion.

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the first patient has been dosed in Delivir, a Phase I clinical trial evaluating TG6050.

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the first quarter ended March 31, 2023.

Bio-Techne announced the launch of two new RNAscope™ in situ Hybridization Probes Kappa and Lambda as analyte specific reagents for the detection of immunoglobulin kappa and lambda light chains mRNA in B-cells.